( NASDAQ-NMS:WCRX,NYSE:ACT )

News from Actavis plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 27, 2015, 09:00 ET Infectious Disease Experts, Scientists and Clinicians Join Forces on SHARE ID™ to Accelerate the Battle Against Antibiotic-resistant Infections

NEW YORK, May 27, 2015 /PRNewswire/-- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company committed to infectious disease...


May 22, 2015, 16:05 ET Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR

 Actavis plc (NYSE: ACT) today confirmed that a panel of the U.S. Court of Appeals for the Second Circuit has issued a ruling upholding a...


May 20, 2015, 16:05 ET Actavis to Present at Bernstein's Thirty-First Annual Strategic Decisions Conference 2015

 Actavis plc (NYSE: ACT), a leading global pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will...


May 18, 2015, 08:00 ET Actavis Launches NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease

 Actavis plc (NYSE: ACT) today announced that NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a...


May 12, 2015, 16:05 ET Actavis to Present at UBS Global Healthcare Conference 2015

 Actavis plc (NYSE: ACT), a leading global pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will...


May 11, 2015, 06:30 ET Actavis Reports Exceptional Performance in First Quarter 2015 with 59% Increase in Net Revenue to $4.2 Billion and 23% Growth in Non-GAAP EPS to $4.30

Actavis plc (NYSE: ACT) today reported continued exceptional performance with net revenue increasing 59 percent to $4.23 billion for the quarter...


May 07, 2015, 16:05 ET Actavis to Re-launch Generic Pulmicort RESPULES® Following Favorable Appeals Court Ruling

 Actavis plc (NYSE: ACT) today announced that it will immediately re-launch its generic version of AstraZeneca's Pulmicort RESPULES®...